Answers are grounded in this paper and cite their sources.
α-Terpineol is a naturally occurring plant-derived compound that has attracted increasing attention for its potential anticancer properties. However, its practical use is limited by poor stability and low bioavailability. To overcome these challenges, we developed a chitosan-based nanoparticle system designed to improve its delivery and biological performance. In this study, α-terpineol-loaded chitosan nanoparticles (α-T-Ch-NPs) were successfully prepared and characterized. The formulation showed a uniform nanoscale size of about 299 nm, a low polydispersity index (0.3), and a stable positive surface charge (+24.61 mV). The encapsulation efficiency (87%) and drug loading capacity (72%) confirmed effective incorporation of α-terpineol within the nanocarrier system. The anticancer potential of the formulation was evaluated in HT29 colon cancer cells, where α-T-Ch-NPs reduced cell viability in a dose-dependent manner. Gene expression analysis showed increased expression of pro-apoptotic markers (Bax and caspase-8) and decreased expression of anti-apoptotic Bcl-2, suggesting activation of apoptosis-related pathways, although the exact molecular pathway requires further confirmation. For safety assessment, healthy Balb/c mice were orally treated with α-T-Ch-NPs at doses of 50 and 100 mg/kg for 28 days. The formulation was well tolerated, with no signs of liver or kidney toxicity. Histological examination confirmed normal tissue architecture, and biochemical markers remained stable. Changes in antioxidant enzyme levels (SOD, CAT, and GPx) indicated an interaction with the body’s natural redox balance; however, these findings primarily reflect good biocompatibility rather than confirmed therapeutic antioxidant effects. Overall, this study suggests that α-T-Ch-NPs are a promising and safe nano-delivery system that enhances the in vitro anticancer activity of α-terpineol. Further studies in tumor-bearing models are needed to confirm their therapeutic potential in vivo.
No takes yet. Share an insight, caveat, or question.
Taheri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: